Hematology
Suppressed hematopoiesis is persistent in chronic hepatitis C patients
Published in Hepatitis Weekly, August 8th, 2005
"Treatment of chronic hepatitis C with interferon (IFN)-alpha and ribavirin has hematotoxic effects. We evaluated the effects of four different IFN/IFN-ribavirin treatment regimens on hematopoiesis. Hematopoiesis was studied in 133 patients with chronic hepatitis C receiving IFN-alpha 2b alone (group A) or in combination with ribavirin (group B), pegylated IFN-alpha 2a (group C), or pegylated IFN-alpha 2b (group D) in combination with ribavirin," researchers in Austria report.
"At week 4, hemoglobin levels were diminished in all groups receiving combination therapy. In the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-08-08)
More Articles from Hepatitis Weekly
- Endocrinology
Insulin resistance triggers hepatitis C-related liver steatosis and fibrosis - Hepatitis B Virus
Occult hepatitis B may hamper interferon in hepatitis C coinfected patients - Hepatitis C Therapy
Short courses of peginterferon clear hepatitis C genotypes 2 or 3 - Rheumatology
Hepatitis C virus infection is not a cause of fibromyalgia - Transplant Medicine
Combination therapy is problematic after hepatitis C-related liver transplants - Allergy & Immunology
Innate immunity overwhelms adenoviral gene expression in the liver - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
